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We present a case of a 79-year-old male who presented with retroperitoneal hematoma a week after motor vehicle accident. Prior
history and family history of bleeding were nonsignificant. His activated partial thromboplastin time was found to be prolonged in
the emergency department. Further workup with coagulation studies showed decreased factor VIII, vWF antigen, and vWF:
ristocetin cofactor assay, and negative Bethesda assay, indicating acquired von Willebrand disease. Immunofluorescence to find an
underlying etiology was suggestive of MGUS. Management of AvWD depends on controlling active bleeding and treating the
underlying cause. He was treated with factor VIII, haemate-p, rituximab, two cycles of IVIg, and three weeks of oral steroids.

1. Introduction
Acquired von Willebrand disease (AvWD) is a rare bleeding
disorder [1, 2]. It is characterized by hemorrhagic events
later in life without personal or family history of bleeding
events [3]. A number of acquired conditions have been
associated with AvWD [4]. We report a patient diagnosed
with acquired von Willebrand disease secondary to monoclonal gammopathy with unknown significance after initial
presentation with retroperitoneal hematoma.

2. Case Description
A 79-year-old man presented to the emergency department
with severe left hip and groin pain with overlying hematoma.
He had a prior admission one week before with arrhythmiainduced syncope leading to a motor vehicle accident. He
received a dual-chamber automatic implantable cardioverterdefibrillator after inducible ventricular fibrillation/ventricular
tachycardia during electrophysiology study. CT scan at the
time was unremarkable except for a 2 cm area of suspected
hematoma in the left trochanteric region. His past medical
history and medications were not significant except for

aspirin use. The patient denied significant prior or family
history of bleeding or easy bruising. He had undergone an
appendectomy and bilateral hip replacements in the past
without significant bleeding.
The patient was hypotensive on presentation. His hemoglobin had dropped from 11.7 g/dl to 6.2 g/dl within one
week. CT scan of his chest/abdomen/pelvis revealed a large
left retroperitoneal hematoma measuring approximately
14.2 × 6.8 × 14.1 cm (Figure 1). The patient’s PTT was 48 s,
which increased from 38 s a week ago (Table 1). His prothrombin time was 13.9 s with INR of 1.1. His white blood
count and platelet count were normal. Serum fibrinogen,
fibrin degradation products and d-dimer, and liver function
tests were normal. His factor VIII activity was 12%, and von
Willebrand factor antigen was 4%. vWF had normal multimeric distribution. His vWF:ristocetin cofactor assay
was < 20. The Bethesda assay (factor VIII inhibitor screening) was negative for an inhibitor. Circulating anticoagulant
screening (mixing study) failed to correct his PTT which
suggested the possibility of an inhibitor or lupus anticoagulant. Although he was positive for lupus anticoagulant
(anti-LA 67), dilute Russell viper venom time (DRVVT)
ratio was 1. Thus, we ruled out antiphospholipid antibody

2

Case Reports in Oncological Medicine

Figure 1: CT scan of the abdomen with retroperitoneal hematoma.
Table 1: Lab tests done during presentation, treatment, and a month after treatment.
Lab test
INR
PTT (sec)
Factor VIII activity (%)
Factor IX activity (%)
Factor XI activity
Factor XII activity
vWF antigen (%)
Ristocetin cofactor assay (%)
vWF multimer analysis
Bethesda assay

Presentation
1.1
48
12
166
98
54
6
< 20
Normal
0

During treatment (3 days)
N/A
N/A
33
N/A
N/A
N/A
10
< 20
N/A
N/A

1 month after treatment
1.1
34.9
114
N/A
N/A
N/A
95
81
N/A
N/A

Reference range
0.9–1.1
23–34 s
50–160%
60–150%
50–150%
50–150%
60–150%
50–160%
Normal multimeric distribution
0

INR: international normalized ratio; PTT: partial thromboplastin time; vWF: von Willebrand factor; N/A: not available.

syndrome and diagnosed the patient’s condition as acquired von Willebrand factor deficiency. The patient was
resuscitated with 3 units of packed red blood cells and
prothrombin complex concentrate. He underwent factor
VIII 50% replacement, one dose of haemate-p (3976 units),
one cycle of rituximab, and three weeks of oral steroids. He
also received two cycles of IVIg which normalized vWF
antigen or factor VIII activity. His aPTT was 34.9 s, factor
VIII activity was 114%, von Willebrand factor antigen was
95%, and vWF:ristocetin cofactor assay was 81%.
Evaluation of underlying etiology showed decreased
albumin and IgG with normal IgA and IgM on serum
electrophoresis. Immunofluorescence showed a band in IgG
lambda suggestive of an early monoclonal protein (0.34 g/dL
of the total 0.68 g/dL of protein in the gamma region).
Kappa/lambda ratio was 0.70 (normal reference range
0.26–1.65). He was diagnosed with monoclonal gammopathy of unknown significance. Bone marrow biopsy to rule
out myeloma was not done. CT scans of head, chest, abdomen, and pelvis done were negative for lytic bone lesions
or lymphadenopathy. He had normal renal function and
normal serum calcium. Iron profile showed ferritin of
925 ng/ml (27–300 ng/dl), iron of 25 mcg/dl (40–175 mcg/dl),
and transferrin of 125 mg/dl (193–378 mg/dl). Ferritin was

most likely elevated from blood transfusions. Folate and
vitamin B12 were normal. ANA, hepatitis B, and hepatitis
C were negative. Thyroid function test was normal. Echocardiogram showed mild aortic stenosis. He was discharged
on 40 mg prednisone daily after bleeding was controlled.
His hemoglobin level on discharge was 9.8 gm/dl.
On follow-up after a month on prednisone, his aPTT was
34.9, factor VIII activity was 114%, von Willebrand factor antigen was 95%, and vWF:ristocetin cofactor assay was 81%. His
hemoglobin was 11.8 g/dl. Repeat iron studies were not done.

3. Discussion
Acquired vWS is a rare condition [5]. It is associated with
a multitude of conditions, including lymphoproliferative
disorders (most common: 48%), myeloproliferative disorders
(chronic granulocytic leukemia, essential thrombocythemia,
and polycythemia vera), neoplasms (Wilms tumor), immunological disorders, cardiovascular diseases, hypothyroidism,
hemoglobinopathies, drugs (valproate, ciprofloxacin, and
hydroxyethyl starch), and infections [1, 2, 4–7]. Among
lymphoproliferative disorders, MGUS is the most commonly associated with AvWD, including in 23% of registered patients [1]. Other lymphoproliferative disorders

Case Reports in Oncological Medicine
associated with acquired vWD are MM, Waldenstrom
macroglobulinemia, CLL, HCL, NHL, and lymphosarcoma
[3]. There are two proposed mechanisms for acquired vWD.
Immune mechanism is believed to be the responsible
mechanism in patients with lymphoproliferative or autoimmune diseases. Nonspecific antibodies bind to vWF; this
complex gets cleared by FC-bearing cells or autoantibodies
directed against the vWF [5, 8]. In MGUS, as in our patient,
paraproteins bind to vWF resulting in accelerated clearance
and low circulating levels [2]. Immune-mediated cause most
likely mediates the disease process in our patient, as he had
significant response to IVIg. Nonimmune-mediated mechanisms are thought to be due to loss of large vWF multimers
under high shear stress conditions (congenital heart defects,
aortic stenosis, artificial heart valves, or left ventricular assist
device), absorption of vWF onto tumor cells, decreased
synthesis (hypothyroidism and valproic acid) or release
from endothelial cells, or increased proteolysis of vWF
(ciprofloxacin) [2, 4, 5].
Presentation in acquired vWD is similar to congenital
vWD. However, AvWD presents later in life with no previous or family history of bleeding [9, 10]. Routine recommended tests in acquired von Willebrand disease are
vWF:Ag assay, vWF:Ag activity assay, and ristocetin cofactor
assay (vWF:RCo/Ag ratio) (normal  1) [2, 7]. Among them,
ristocetin cofactor assay is the recommended test [7]. vWF:
RCo/Ag ratio < 0.6–0.7 indicates inhibitory antibodies or
a selective loss or decrease in high molecular weight multimers [2]. Circulating inhibitors are rarely detected in this
condition [4]. vWF multimer analysis is the gold standard
test. It is particularly useful if other tests are negative [2].
A multimeric pattern with decreased levels of high molecular weight vWF multimers is seen because the inhibitors
tend to attack the large multimers of vWF. Serum protein
electrophoresis or immunofluorescence tests and thyroid
function test can be done to establish etiology [4]. Congenital vWD and AvWD can be differentiated by measurement of vWF propeptide (vWFAg II). vWF propeptide
is a marker of vWF synthesis. Since AvWD is associated
with clearance of vWF, vWF propeptide will be normal [4].

4. Management
Management is based on correction of acute bleeding episode and treatment of associated underlying conditions.
The acute bleeding can be controlled by infusion of cryoprecipitate, vWF-containing factor VIII (FVIII) concentrates (haemate-p), or desmopressin. This will result in
immediate and transient rise in serum FVIII-vWF complex
levels [4]. IVIg can correct vWF activity for 2–3 weeks [2].
IVIg is the preferred to minimize bleeding risk during elective
procedures [1]. A combination of IVIg, vWF-containing
factor VIII (FVIII) concentrates (haemate-p), and desmopressin is effective in some patients [5]. FVIII and vWF levels
return to baseline within 2 hours of transfusion of haemate-p
[11]. In patients with MGUS, steroids and rituximab have
been used to treat AvWD [5]. Rituximab, which is effective in
acquired hemophilia, has been used in treatment for a few
cases. However, it has been reported to be ineffective in them
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[12]. Management of aortic stenosis, hypothyroidism, and
discontinuation of medications has resulted in correction of
the bleeding disorder [2].

5. Conclusion
AvWD should be considered in cases with abnormal
bleeding and prolonged PTT. It can be asymptomatic in mild
conditions for decades [2]. Further workup for an etiology is
important as treatment of the underlying cause can prevent
future bleeding episodes.
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